{"product_id":"gild-ansoff-matrix","title":"Gilead Sciences, Inc. (GILD): Ansoff Matrix [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Ansoff Matrix Analysis of Gilead Sciences, Inc. gives you a practical, research-based view of growth options across market penetration, market development, product development, and diversification. You'll see how the company can defend Biktarvy in U.S. HIV, expand Yeztugo and Livdelzi, push HIV licenses across \u003cstrong\u003e120-plus countries\u003c\/strong\u003e, develop BIC\/LEN and other new combinations, and manage risks tied to approvals, confirmatory trials, and scaling beyond core HIV and hepatitis markets.\u003c\/p\u003e\u003ch2\u003eGilead Sciences, Inc. - Ansoff Matrix: Market Penetration\u003c\/h2\u003e\n\u003cp\u003eGilead Sciences, Inc. uses market penetration by pushing more volume through existing HIV and PBC products, keeping patients on therapy, and widening access in the U.S. The main numeric anchors are \u003cstrong\u003e$11.8 billion\u003c\/strong\u003e in Biktarvy 2023 sales, about \u003cstrong\u003e1.2 million\u003c\/strong\u003e people living with HIV in the U.S., \u003cstrong\u003e31,800\u003c\/strong\u003e new HIV diagnoses in 2022, and a \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e CymaBay acquisition for Livdelzi.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket area\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003ePenetration use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$11.8 billion\u003c\/strong\u003e 2023 sales; \u003cstrong\u003e50 mg\u003c\/strong\u003e\/\u003cstrong\u003e200 mg\u003c\/strong\u003e\/\u003cstrong\u003e25 mg\u003c\/strong\u003e; \u003cstrong\u003e1\u003c\/strong\u003e tablet once daily\u003c\/td\u003e\n\u003ctd\u003eDefend U.S. HIV leadership\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. HIV base\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e1.2 million\u003c\/strong\u003e people living with HIV; \u003cstrong\u003e31,800\u003c\/strong\u003e new diagnoses in 2022\u003c\/td\u003e\n\u003ctd\u003eSupports treatment and prevention volume\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivdelzi\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e CymaBay acquisition; \u003cstrong\u003e10 mg\u003c\/strong\u003e once daily\u003c\/td\u003e\n\u003ctd\u003eGrow share in PBC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral regimen burden\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e365\u003c\/strong\u003e daily dosing opportunities per year versus \u003cstrong\u003e2\u003c\/strong\u003e doses per year for a 6-month regimen\u003c\/td\u003e\n\u003ctd\u003eSupports adherence and persistence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eBiktarvy is the clearest market penetration asset because it already sits on a large installed base. The regimen is a fixed-dose combination of bictegravir \u003cstrong\u003e50 mg\u003c\/strong\u003e, emtricitabine \u003cstrong\u003e200 mg\u003c\/strong\u003e, and tenofovir alafenamide \u003cstrong\u003e25 mg\u003c\/strong\u003e in \u003cstrong\u003e1\u003c\/strong\u003e once-daily tablet. That matters in a U.S. market with about \u003cstrong\u003e1.2 million\u003c\/strong\u003e people living with HIV, because share defense depends on keeping patients on a familiar regimen instead of losing them to older or more complex options. Biktarvy also had \u003cstrong\u003e$11.8 billion\u003c\/strong\u003e in 2023 revenue, so even small share losses would be financially material.\u003c\/p\u003e\n\n\u003cp\u003eYeztugo's prevention uptake depends on reducing friction in a market that still saw \u003cstrong\u003e31,800\u003c\/strong\u003e new HIV diagnoses in 2022. In market penetration terms, the point is not just launch volume; it is getting more at-risk patients onto a prevention regimen and keeping them there. A long-acting schedule with \u003cstrong\u003e2\u003c\/strong\u003e doses per year lowers the annual dosing burden from \u003cstrong\u003e365\u003c\/strong\u003e daily pill events to \u003cstrong\u003e2\u003c\/strong\u003e clinic administrations. That gap matters because adherence is the main reason prevention regimens fail in real-world use.\u003c\/p\u003e\n\n\u003cp\u003eLivdelzi is a smaller but still important penetration play because PBC, or primary biliary cholangitis, is a specialty market where diagnosis, specialist prescribing, and persistence drive share. Gilead paid \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e for CymaBay, showing the size of the bet. The product is a \u003cstrong\u003e10 mg\u003c\/strong\u003e once-daily oral therapy, which fits a market penetration strategy built on convenience and repeat prescribing rather than one-time use. In a rare-disease market, every incremental prescription matters more than broad consumer awareness.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e365\u003c\/strong\u003e daily dosing events per year make refill continuity critical for HIV treatment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e doses per year can cut missed-dose risk sharply versus daily oral prevention.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$11.8 billion\u003c\/strong\u003e Biktarvy sales show the financial value of defending an existing franchise.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e for CymaBay shows how much Gilead is willing to spend to add PBC share.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e31,800\u003c\/strong\u003e new U.S. HIV diagnoses in 2022 keep prevention demand high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAccess programs across HIV franchises matter because the difference between approval and actual use is usually payer friction, not clinical efficacy. If a patient faces prior authorization, refill delays, or a copay problem on a daily regimen, the result is lost volume across \u003cstrong\u003e365\u003c\/strong\u003e possible dosing points a year. For Gilead, access support protects the installed base of Biktarvy and other oral HIV products and helps convert prevention interest into filled prescriptions. That makes access part of market penetration, not a side activity.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003eDose\u003c\/td\u003e\n\u003ctd\u003eDosing frequency\u003c\/td\u003e\n\u003ctd\u003ePenetration role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50 mg\u003c\/strong\u003e\/\u003cstrong\u003e200 mg\u003c\/strong\u003e\/\u003cstrong\u003e25 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet daily\u003c\/td\u003e\n\u003ctd\u003eCore HIV treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDescovy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e200 mg\u003c\/strong\u003e\/\u003cstrong\u003e25 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet daily\u003c\/td\u003e\n\u003ctd\u003eTreatment and PrEP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenvoya\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e150 mg\u003c\/strong\u003e\/\u003cstrong\u003e150 mg\u003c\/strong\u003e\/\u003cstrong\u003e200 mg\u003c\/strong\u003e\/\u003cstrong\u003e10 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet daily\u003c\/td\u003e\n\u003ctd\u003eSwitch and maintenance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOdefsey\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e200 mg\u003c\/strong\u003e\/\u003cstrong\u003e25 mg\u003c\/strong\u003e\/\u003cstrong\u003e25 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet daily\u003c\/td\u003e\n\u003ctd\u003eMaintenance therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTruvada\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e200 mg\u003c\/strong\u003e\/\u003cstrong\u003e300 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet daily\u003c\/td\u003e\n\u003ctd\u003ePrEP and treatment history\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivdelzi\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10 mg\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e capsule daily\u003c\/td\u003e\n\u003ctd\u003ePBC share building\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eOnce-daily oral regimens support adherence because they keep the routine simple. In HIV, simplicity is a commercial advantage: fewer dosing steps usually means fewer missed doses, fewer abandoned prescriptions, and better retention. In practical terms, a patient choosing between a \u003cstrong\u003e1\u003c\/strong\u003e-pill daily regimen and a more complex schedule is comparing \u003cstrong\u003e365\u003c\/strong\u003e annual dosing opportunities with a smaller number of clinic-based events in long-acting prevention. That is why Gilead's market penetration strategy keeps leaning on fixed-dose combinations, refill continuity, and access support.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e2018\u003c\/strong\u003e Biktarvy approval supports a large installed base for repeat prescribing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2019\u003c\/strong\u003e Descovy PrEP approval broadened the prevention portfolio.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2012\u003c\/strong\u003e Truvada PrEP approval created an older prevention base that still informs switching behavior.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e CymaBay acquisition expanded the non-HIV franchise into PBC.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eGilead Sciences, Inc. - Ansoff Matrix: Market Development\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e120-plus countries\u003c\/strong\u003e is the clearest market-development number in Gilead Sciences, Inc.'s HIV strategy. The company's partner-led model lets it reach more geographies without building full commercial infrastructure in each one.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMarket-development move\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV licenses\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e120-plus\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eBroadens access through partner markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV manufacturing partners\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers\u003c\/td\u003e\n\u003ctd\u003eSupports supply scale across licensed markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal HIV burden\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e39.9 million\u003c\/strong\u003e people living with HIV in 2023\u003c\/td\u003e\n\u003ctd\u003eShows the size of the prevention and treatment pool\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivdelzi U.S. launch base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e approved U.S. market in 2024\u003c\/td\u003e\n\u003ctd\u003eCreates the starting point for ex-U.S. filings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy breast cancer evidence base\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e529\u003c\/strong\u003e patients in ASCENT; \u003cstrong\u003e543\u003c\/strong\u003e patients in TROPiCS-02\u003c\/td\u003e\n\u003ctd\u003eSupports expansion into more oncology settings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal cancer burden\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20 million\u003c\/strong\u003e new cancer cases in 2022\u003c\/td\u003e\n\u003ctd\u003eShows the size of the oncology market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eExpand HIV licenses across 120-plus countries\u003c\/h3\u003e\n\n\u003cp\u003eGilead Sciences, Inc. uses voluntary licensing to push HIV access into \u003cstrong\u003e120-plus\u003c\/strong\u003e countries and territories. That matters because the company can scale reach faster than a country-by-country direct launch model. It also lowers the need for duplicate commercial teams, local packaging systems, and standalone distribution networks.\u003c\/p\u003e\n\n\u003cp\u003eThe license structure is built around \u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers. That number matters because manufacturing capacity is part of market development, not just supply chain management. In HIV, access is tied to both product availability and price, and the licensed-manufacturer model is designed to serve large public-health markets more efficiently than direct export alone.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e120-plus\u003c\/strong\u003e countries and territories are inside the access footprint.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers are part of the supply model.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e39.9 million\u003c\/strong\u003e people were living with HIV globally in 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eBroaden Yeztugo access outside the U.S.\u003c\/h3\u003e\n\n\u003cp\u003eYeztugo's market-development path outside the U.S. sits on the same \u003cstrong\u003e120-plus-country\u003c\/strong\u003e access structure. In practical terms, that means Gilead Sciences, Inc. can use partner markets to widen reach instead of relying only on a U.S.-first commercial launch model.\u003c\/p\u003e\n\n\u003cp\u003eThis matters because HIV prevention demand is global, not local. With \u003cstrong\u003e39.9 million\u003c\/strong\u003e people living with HIV in 2023, the commercial case for international access is tied to geography as much as to clinical demand. The key market-development issue is how fast the product can move from one approved market to many licensed markets.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e120-plus\u003c\/strong\u003e countries define the ex-U.S. access map.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e manufacturers give Gilead Sciences, Inc. more than one supply channel.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e39.9 million\u003c\/strong\u003e people living with HIV in 2023 show the scale of need.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eInternationalize Livdelzi where approved\u003c\/h3\u003e\n\n\u003cp\u003eLivdelzi gives Gilead Sciences, Inc. a second geography-expansion path outside HIV. The real-life base is a \u003cstrong\u003e2024\u003c\/strong\u003e U.S. approval for primary biliary cholangitis, which starts the internationalization process from \u003cstrong\u003e1\u003c\/strong\u003e approved major market rather than from zero.\u003c\/p\u003e\n\n\u003cp\u003eFor market development, that first approval matters because every additional country can be approached through the same clinical dossier, regulatory package, and launch sequence. The product does not need to change for each country; the geography does. That is the core Ansoff logic.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e U.S. approval base in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe approved indication is primary biliary cholangitis.\u003c\/li\u003e\n\u003cli\u003eThe market-development task is filing in additional countries where regulators accept the data package.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eExtend Trodelvy use into more oncology markets\u003c\/h3\u003e\n\n\u003cp\u003eTrodelvy already has a proven oncology expansion base. In the U.S., it reached \u003cstrong\u003e2\u003c\/strong\u003e metastatic breast cancer settings, and its evidence base includes \u003cstrong\u003e529\u003c\/strong\u003e patients in ASCENT and \u003cstrong\u003e543\u003c\/strong\u003e patients in TROPiCS-02. Those numbers matter because oncology label expansion usually depends on late-stage data, not just early clinical signals.\u003c\/p\u003e\n\n\u003cp\u003eThe broader market is large. Global cancer incidence reached \u003cstrong\u003e20 million\u003c\/strong\u003e new cases in 2022. That makes oncology one of the most attractive market-development areas for Gilead Sciences, Inc., especially when a product can move from one approved breast-cancer setting into additional lines of therapy or other tumor types.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e approved metastatic breast cancer settings in the U.S.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e529\u003c\/strong\u003e patients were enrolled in ASCENT.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e543\u003c\/strong\u003e patients were enrolled in TROPiCS-02.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e20 million\u003c\/strong\u003e new cancer cases in 2022 show the size of the market.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eUse global manufacturing to support launches\u003c\/h3\u003e\n\n\u003cp\u003eGlobal manufacturing is what makes the geographic plan workable. For HIV prevention, Gilead Sciences, Inc. has a network built around \u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers and \u003cstrong\u003e120-plus\u003c\/strong\u003e countries. That structure supports launch volume, local supply continuity, and faster country coverage than a single-site model would allow.\u003c\/p\u003e\n\n\u003cp\u003eThis is especially important in markets where access depends on price, tendering, and public procurement. In those settings, manufacturing reach is part of market development because the company can enter more countries without carrying the full cost of local production in each one.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers support scale.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e120-plus\u003c\/strong\u003e countries expand the addressable footprint.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e39.9 million\u003c\/strong\u003e people living with HIV in 2023 show why supply scale matters.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e20 million\u003c\/strong\u003e new cancer cases in 2022 show why oncology launches need broad manufacturing support.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eGilead Sciences, Inc. - Ansoff Matrix: Product Development\u003c\/h2\u003e\n\n\u003cp\u003eGilead Sciences is using product development to extend its HIV, oncology, and liver disease pipelines with assets tied to \u003cstrong\u003e2018\u003c\/strong\u003e, \u003cstrong\u003e2020\u003c\/strong\u003e, \u003cstrong\u003e2022\u003c\/strong\u003e, and \u003cstrong\u003e2024\u003c\/strong\u003e milestones. The strategy depends on new dosing formats, new combinations, and new indications rather than entirely new therapeutic categories.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct-development move\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life numeric anchors\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003ePipeline focus\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBIC\/LEN\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2018\u003c\/strong\u003e; \u003cstrong\u003e2022\u003c\/strong\u003e; \u003cstrong\u003e927 mg\u003c\/strong\u003e; \u003cstrong\u003e300 mg\u003c\/strong\u003e; \u003cstrong\u003e6 months\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHIV treatment option built from bictegravir and lenacapavir platforms\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLenacapavir prevention\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e infections; \u003cstrong\u003e2,134\u003c\/strong\u003e participants; \u003cstrong\u003e2\u003c\/strong\u003e infections; \u003cstrong\u003e26\u003c\/strong\u003e weeks\u003c\/td\u003e\n\u003ctd\u003eTwice-yearly HIV prevention\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy combinations\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2020\u003c\/strong\u003e; \u003cstrong\u003e2023\u003c\/strong\u003e; \u003cstrong\u003e5.6\u003c\/strong\u003e months; \u003cstrong\u003e1.7\u003c\/strong\u003e months; \u003cstrong\u003e12.1\u003c\/strong\u003e months; \u003cstrong\u003e6.7\u003c\/strong\u003e months; phase \u003cstrong\u003e3\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eEarlier-line oncology combinations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivdelzi\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e; \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePrimary biliary cholangitis pipeline expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenesis AI\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2023\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSmall-molecule discovery collaboration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eLaunch BIC\/LEN as a new HIV option\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eGilead Sciences already has 2 approved HIV platforms that shape this move. Biktarvy was approved in \u003cstrong\u003e2018\u003c\/strong\u003e as a once-daily, single-tablet regimen, and Sunlenca was approved on \u003cstrong\u003eDecember 22, 2022\u003c\/strong\u003e as the first twice-yearly HIV capsid inhibitor. Sunlenca uses \u003cstrong\u003e927 mg\u003c\/strong\u003e subcutaneous dosing on days \u003cstrong\u003e1\u003c\/strong\u003e and \u003cstrong\u003e2\u003c\/strong\u003e, then \u003cstrong\u003e927 mg\u003c\/strong\u003e every \u003cstrong\u003e6 months\u003c\/strong\u003e, with \u003cstrong\u003e300 mg\u003c\/strong\u003e oral tablets on days 1 and 2.\u003c\/p\u003e\n\n\u003cp\u003eThat creates the product-development base for a BIC\/LEN option. The combination links a bictegravir-based daily treatment platform with a long-acting lenacapavir platform, which matters in HIV because dosing frequency is a major driver of adherence and patient preference.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2018\u003c\/strong\u003e: Biktarvy approval\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2022\u003c\/strong\u003e: Sunlenca approval\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e927 mg\u003c\/strong\u003e: Sunlenca injection dose\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e6 months\u003c\/strong\u003e: maintenance interval for Sunlenca\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdvance lenacapavir-based prevention products\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eLenacapavir prevention is tied to the PURPOSE phase \u003cstrong\u003e3\u003c\/strong\u003e program. In PURPOSE 1, the lenacapavir arm had \u003cstrong\u003e0\u003c\/strong\u003e HIV infections among \u003cstrong\u003e2,134\u003c\/strong\u003e participants. In PURPOSE 2, the lenacapavir arm reported \u003cstrong\u003e2\u003c\/strong\u003e HIV infections. The prevention schedule is \u003cstrong\u003e2\u003c\/strong\u003e injections per year, or every \u003cstrong\u003e26\u003c\/strong\u003e weeks.\u003c\/p\u003e\n\n\u003cp\u003eThe market need is large. Global HIV figures for \u003cstrong\u003e2023\u003c\/strong\u003e were \u003cstrong\u003e39.9 million\u003c\/strong\u003e people living with HIV and \u003cstrong\u003e1.3 million\u003c\/strong\u003e new infections. Those numbers give lenacapavir prevention a clear commercial and public-health case for a twice-yearly product.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e infections in PURPOSE 1 lenacapavir arm\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e infections in PURPOSE 2 lenacapavir arm\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e26\u003c\/strong\u003e-week dosing interval\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e39.9 million\u003c\/strong\u003e people living with HIV globally in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1.3 million\u003c\/strong\u003e new HIV infections globally in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDevelop new oncology combinations for Trodelvy\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eTrodelvy was first approved in \u003cstrong\u003e2020\u003c\/strong\u003e, and Gilead expanded it in \u003cstrong\u003e2023\u003c\/strong\u003e to a second breast cancer setting. In the ASCENT study, median progression-free survival was \u003cstrong\u003e5.6\u003c\/strong\u003e months versus \u003cstrong\u003e1.7\u003c\/strong\u003e months, and median overall survival was \u003cstrong\u003e12.1\u003c\/strong\u003e months versus \u003cstrong\u003e6.7\u003c\/strong\u003e months.\u003c\/p\u003e\n\n\u003cp\u003eGilead is using that base to test new combinations earlier in treatment, including phase \u003cstrong\u003e3\u003c\/strong\u003e work with pembrolizumab in triple-negative breast cancer. The product-development goal is to move Trodelvy from later-line treatment into first-line combination use.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2020\u003c\/strong\u003e: initial Trodelvy approval\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e: second breast cancer approval\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e: approved breast cancer settings\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e5.6\u003c\/strong\u003e months versus \u003cstrong\u003e1.7\u003c\/strong\u003e months: ASCENT median progression-free survival\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e12.1\u003c\/strong\u003e months versus \u003cstrong\u003e6.7\u003c\/strong\u003e months: ASCENT median overall survival\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eComplete confirmatory trials for Livdelzi\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eGilead agreed to acquire CymaBay for \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e, bringing seladelpar into the company's liver disease pipeline. The development focus is primary biliary cholangitis, where confirmatory trial completion is central to long-term commercial use.\u003c\/p\u003e\n\n\u003cp\u003eThat acquisition size matters because it shows Gilead is paying for late-stage pipeline assets rather than starting from zero. In product-development terms, Livdelzi adds a new liver disease program with a defined regulatory and clinical path.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e: CymaBay acquisition value\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e: transaction year\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e: phase 3 development stage used for confirmatory work\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eUse Genesis AI for new small molecules\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eGilead and Genesis Therapeutics announced a collaboration in \u003cstrong\u003e2023\u003c\/strong\u003e to discover new small molecules. This is early-stage product development, before clinical testing, where the goal is to produce better preclinical candidates for later trials.\u003c\/p\u003e\n\n\u003cp\u003eThe strategic value sits in the number of shots on goal. A \u003cstrong\u003e2023\u003c\/strong\u003e AI-enabled discovery deal gives Gilead another route into HIV, oncology, and liver disease candidates without relying only on internal chemistry programs.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2023\u003c\/strong\u003e: collaboration year\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSmall molecules\u003c\/strong\u003e: discovery target class\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e: approved-drug output at the collaboration stage\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eGilead Sciences, Inc. - Ansoff Matrix: Diversification\u003c\/h2\u003e\n\u003cp\u003eGilead Sciences, Inc. has already used diversification to move into oncology and liver disease through three large transactions: Kite Pharma for \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e in 2017, Immunomedics for about \u003cstrong\u003e$21 billion\u003c\/strong\u003e in 2020, and CymaBay Therapeutics for \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e in 2024.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eDiversification area\u003c\/th\u003e\n\u003cth\u003eReal-life event\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell therapy oncology\u003c\/td\u003e\n\u003ctd\u003eKite Pharma acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.9 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2017\u003c\/td\u003e\n\u003ctd\u003eBrought Yescarta and Tecartus into Gilead Sciences, Inc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSolid tumor oncology\u003c\/td\u003e\n\u003ctd\u003eImmunomedics acquisition\u003c\/td\u003e\n\u003ctd\u003eabout \u003cstrong\u003e$21 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2020\u003c\/td\u003e\n\u003ctd\u003eBrought Trodelvy into Gilead Sciences, Inc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver disease and inflammation\u003c\/td\u003e\n\u003ctd\u003eCymaBay Therapeutics acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eBrought seladelpar into Gilead Sciences, Inc.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore revenue concentration\u003c\/td\u003e\n\u003ctd\u003eBiktarvy 2024 sales\u003c\/td\u003e\n\u003ctd\u003emore than \u003cstrong\u003e$13 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003eShows why diversification beyond HIV still matters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpand deeper into inflammation beyond PBC\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePrimary biliary cholangitis, or PBC, is an autoimmune liver disease. Gilead Sciences, Inc. paid \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e for CymaBay Therapeutics and received seladelpar, which the FDA approved on \u003cstrong\u003eAugust 14, 2024\u003c\/strong\u003e. That is a real diversification step because it moves the company into immune-mediated liver disease, not just viral infection. The next strategic test is whether Gilead Sciences, Inc. can use the same liver-disease commercial base for additional inflammatory or cholestatic indications.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e created a liver-disease entry point with an approved asset.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAugust 14, 2024\u003c\/strong\u003e turned that asset into a commercial launch.\u003c\/li\u003e\n\u003cli\u003ePBC is separate from HIV and HCV, so the revenue risk is not tied to antivirals.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBuild broader oncology pipeline beyond HIV\/HCV\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOncology is the clearest diversification lane after virology. Kite Pharma gave Gilead Sciences, Inc. two approved CAR-T therapies, Yescarta and Tecartus, and the \u003cstrong\u003e$21 billion\u003c\/strong\u003e Immunomedics deal added Trodelvy, an antibody-drug conjugate. These are different technologies, different manufacturing steps, and different prescribers, so they reduce the company's dependence on HIV and HCV demand. In 2024, Biktarvy still generated more than \u003cstrong\u003e$13 billion\u003c\/strong\u003e in sales, which shows why oncology has to keep growing if Gilead Sciences, Inc. wants a more balanced mix.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eYescarta and Tecartus sit in cell therapy, not antivirals.\u003c\/li\u003e\n\u003cli\u003eTrodelvy sits in solid-tumor oncology, not virology.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003e2020\u003c\/strong\u003e Immunomedics deal expanded the company into a second major oncology platform.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInvest in AI-enabled drug discovery platforms\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGilead Sciences, Inc. does not disclose a separate public AI spending line item, so the academic way to treat this move is as an R\u0026amp;D productivity issue, not a reported segment. AI matters most where the company is already diversifying: target selection in oncology, biology work in inflammation, and molecule design in liver disease. If AI shortens the time from target idea to candidate selection, it improves the economics of diversification because fewer failed programs waste capital.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNo separate public AI budget is disclosed.\u003c\/li\u003e\n\u003cli\u003eAI is most useful in early-stage discovery, where failure rates are highest.\u003c\/li\u003e\n\u003cli\u003eIts value shows up through faster pipeline decisions, not immediate sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdd new liver-disease therapies from acquired assets\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe CymaBay Therapeutics acquisition is the clearest example of buying into a new therapeutic area. Gilead Sciences, Inc. moved from viral liver disease history into a marketed therapy for PBC with a \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e purchase and a \u003cstrong\u003e2024\u003c\/strong\u003e FDA approval. That matters because liver disease can become a repeatable franchise only if the company keeps adding assets that fit the same specialist prescriber base and the same medical economics.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e was paid for the acquired liver-disease asset.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e is the first commercial year of the new asset under Gilead Sciences, Inc.\u003c\/li\u003e\n\u003cli\u003eThe move broadens the company beyond HIV and HCV into immune-mediated liver disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eScale manufacturing for future non-core launches\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNon-core launches such as CAR-T and liver-disease therapies need more than clinical success; they need manufacturing capacity, batch control, and supply reliability. Gilead Sciences, Inc. already has commercial experience from two CAR-T products, Yescarta and Tecartus, and one oncology antibody-drug conjugate, Trodelvy. That matters because manufacturing complexity is one of the biggest barriers to diversification, and the company has already paid for that capability through the \u003cstrong\u003e$11.9 billion\u003c\/strong\u003e Kite Pharma deal and the about \u003cstrong\u003e$21 billion\u003c\/strong\u003e Immunomedics deal.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTwo approved CAR-T products already sit inside the portfolio.\u003c\/li\u003e\n\u003cli\u003eOne approved antibody-drug conjugate already sits inside the portfolio.\u003c\/li\u003e\n\u003cli\u003eFuture launches outside HIV and HCV need the same supply discipline.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45497905774741,"sku":"gild-ansoff-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/gild-ansoff-matrix.png?v=1740177765","url":"https:\/\/dcf-model.com\/fr\/products\/gild-ansoff-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}